




- (51) **International Patent Classification:**
A61K 9/10 (2006.01) *A61K 47/10* (2017.01)
- (21) **International Application Number:**
PCT/US2021/014642
- (22) **International Filing Date:**
22 January 2021 (22.01.2021)
- (25) **Filing Language:** English
- (26) **Publication Language:** English
- (30) **Priority Data:**
62/965,738 24 January 2020 (24.01.2020) US
- (71) **Applicant:** TVARDI THERAPEUTICS, INC. [US/US];
2450 Holcombe Blvd Ste X, Houston, TX 77021 (US).
- (72) **Inventors:** ALIBHAI, Imran; 2450 Holcombe Blvd Ste X, Houston, TX 77021 (US). DE ACHAVAL, Sofia; 2450 Holcombe Blvd Ste X, Houston, TX 77021 (US). LANGEVIN, Beverly C.; 2450 Holcombe Blvd Ste X, Houston, TX 77021 (US). ZHOU, Tian; 2450 Holcombe Blvd Ste X, Houston, TX 77021 (US).
- (74) **Agent:** POULOS, Sabrina D. et al.; Goodwin Procter LLP, 100 Northern Avenue, IP Docketing Dept./7TH FL, Boston, MA 02210 (US).
- (81) **Designated States** (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.
- (84) **Designated States** (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,

(54) **Title:** THERAPEUTIC COMPOUNDS, FORMULATIONS, AND USES THEREOF



Error bars calculated from sample standard deviation divided by the square root of the sample size

FIG. 8

(57) **Abstract:** Provided herein are compositions, formulations, and (e.g., oral) dosage forms comprising a compound of Formula (I). In specific instances, such compositions comprise an emulsifier, a solubilizer, a polyethylene glycol, a surfactant, and an antioxidant. In some instances, such compositions are useful for the treatment of fibrosis, cancer, and/or chronic inflammation.

[Continued on next page]



TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*